Dr. Jildaz Caroff
Neuri Brain Vascular Center
Bicêtre Hospital AP-HP
As seen in our recent teaser , mechanical thrombectomy for the management of acute ischemic stroke has successfully spread throughout the world.
This very fast expansion has also been associated with a progressive increase in successful recanalization rates as illustrated in the graph below.
In the shadow of this impressive success lies the tremendous amount of work being accomplished by dedicated preclinical scientists with support from the neurovascular industry – work which might sometimes underestimate.
Last time , we have seen that some specific clinical situations remain very challenging and can be frustrating for physicians. In this second edition of our Special Focus, we will explore how Cerenovus engineers developed their approach to replicating tough clots in the lab , forming the scientific basis for the design and development of a new generation of stent retrievers targeting specific types of clots.
A few years ago, I was lucky enough to spend one year immersed in Matt Gounis’ research lab at UMass, an experience which changed forever how I would see every device going through my hands. During that time, I came to know all the different processes each one of these devices goes through before being used in our everyday procedures. Here, Vania Anagnostakou from UMass presents her journey from clinical practice to preclinical research and discusses the symbiosis between these two worlds.
We will also talk about a new parameter that could be important to take into account while performing mechanical thrombectomies, i.e. the speed of retrieval itself.
If you have ever fought trying to remove a calcified clot, you might be curious to see how different set-ups performed in vitro .
Soon, in the very final edition of this special series, we will focus on clinical studies, the last step from setting a problematic to reaching the goal and providing a solution.